References
- Guptill JT, Soni M, Meriggioli MN. Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis. Neurotherapeutics. 2016;13(1):118–131.
- Carr AS, Cardwell CR, McCarron PO, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10(1):46.
- Verschuuren JJGM, Huijbers MG, Plomp JJ, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12(9):918–923. .
- Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012;8(5):427–438.
- Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun. 2014;52:139–145.
- Gilhus NE, Longo DL. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570.
- Kerty E, Elsais A, Argov Z, et al. EFNS/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol. 2014;21(5):687–693.
- Roda RH, Doherty L, Corse AM. Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Neuromuscul Disord. 2019;29(7):554–561.
- Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis: extended prospective study results. Muscle Nerve. 2018;58(3):452–455.
- Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259–266.
- Deftereos SN. B cells in the pathophysiology of myasthenia gravis: is there a role for cladribine? Muscle Nerve. 2018;58(6):E41.
- Mittag T, Kornfeld P, Tormay A, et al. Detection of anti-acetylcholine receptor factors in serum and thymus from patients with myasthenia gravis. N Engl J Med. 1976;294(13):691–694.
- Lee J-Y, Stathopoulos P, Gupta S, et al. Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol. 2016;3(6):443–454. .
- Mantegazza R, Cavalcante P. Diagnosis and treatment of myasthenia gravis. Curr Opin Rheumatol. 2019;31(6):623–633.
- Habib AA, Ahmadi Jazi G, Mozaffar T. Update on immune-mediated therapies for myasthenia gravis. Muscle Nerve. 2020;62(5):579–592.
- Soliris 300 product information. [cited 2020 Jun 23]. Available from: https://www.ema.europa.eu/documents/product-information/soliris-epar-product-information_en.pdf.
- Howard JFJ, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–9861.
- Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14–24. .
- Alexion Pharmaceuticals, Inc. Eculizumab for use in AChR+ gMG. [cited 2020 Jun 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s422lbl.pdf.
- [cited 2020 Dec 18]. Available from: https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/14/1304-public-summary-opinion-orphan-designation-eculizumab-treatment-myasthenia-gravis_en.pdf
- Sheridan D, Yu ZX, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;12:4)e0195909.
- Safety and efficacy study of Ravulizumab in adults with generalized myasthenia gravis. Accessed 2020 Aug 2. https://clinicaltrials.gov/ct2/show/NCT03920293.
- Ricardo A, Arata M, DeMarco S, et al. Preclinical evaluation of RA101495, a potent cyclic peptide inhibitor of c5 for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2015;126(23): 939–939. DOI:10.1182/blood.V126.23.939.939.
- Howard JF, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor Zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582–592.
- Zilucoplan FDA Approval. Accessed 2020 Jun 23. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=699
- Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist Efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–4386.
- Howard JF, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist Efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661–e2673.
- Argenx announces positive topline phase 3 ADAPT trial results. [cited 2020 Aug 2]. Available from: https://www.argenx.com/news/argenx-announces-positive-topline-phase-3-adapt-trial-results.
- Kiessling P, Lledo-Garcia R, Watanabe S, et al. The FcRn inhibitor Rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Science Translational Medicine. 2017;9(414):eaan1208.
- Howard JF, Bril V, Burns M, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):S43.001.
- A study to test efficacy and safety of Rozanolixizumab in adult patients with generalized myasthenia gravis. [cited 2020 Dec 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT03971422.
- Ling LE, Hillson JL, Tiessen RG, et al. M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study. Clin Pharmacol Ther. 2019;105(4):1031–1039. .
- [cited 2020 Dec 18]. Available from: https://www.globenewswire.com/news-release/2020/06/15/2047945/0/en/Momenta-Pharmaceuticals-Announces-Positive-Topline-Data-from-Interim-Analysis-of-Phase-2-Vivacity-MG-Study-of-Nipocalimab-M281-in-Generalized-Myasthenia-Gravis-gMG.html.
- Collins J, Jones L, Snyder M, et al. RVT-1401, A novel anti-FcRn monoclonal antibody, is well tolerated in healthy subjects and reduces plasma IgG following subcutaneous or intravenous administration. Vol. In. American Academy of Neurology Annual Meeting. Philadelphia: PA; 2019
- Immunovant. Sciences GmbH. A study of RVT-1401 in myasthenia gravis (MG) patients. [cited 2020 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03863080?term=Immunovant&rank=3
- Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive Belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425–e1434. .
- Cordoba F, Wieczorek G, Audet M, et al. A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant. 2015;15(11):2825–283633. .
- [cited 2020 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02565576
- [cited 2020 Dec 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04524273
- Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5p1):859–866.
- Hultin LE, Hausner MA, Hultin PM, et al. Cd20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14(2):196–204.
- Marino M, Bartoccioni E, Alboini PE, et al. Rituximab in myasthenia gravis: a “to be or not to be” inhibitor of T cell function. Ann N Y Acad Sci. 2018;1413(1):41–48.
- BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis - Full Text View - ClinicalTrials.gov. [cited 2020 Jun 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT02110706
- Hehir MK, Hobson-Webb LD, Benatar M, et al. Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology. 2017;89(10):1069–1077.
- Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193.
- Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve. 2012;46(5):687–691.
- Robeson KR, Kumar A, Keung B, et al. Durability of the rituximab response in acetylcholine receptor autoantibody–positive myasthenia gravis. JAMA Neurol. 2017;74(1):60.
- Brauner S, Eriksson-Dufva A, Hietala MA, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77(8):974–981.
- Tandan R, Hehir MK. 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185–196.
- Davies A, Merli F, Mihaljević B, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–e282.
- Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425–440.
- Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007;62(1):43–52.
- Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792–801.
- Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology. 2000;55(7):1062–1063.
- Afanasiev V, Demeret S, Bolgert F, et al. Resistant myasthenia gravis and rituximab: a monocentric retrospective study of 28 patients. Neuromuscul Disord. 2017;27(3):251–258.
- Cortés-Vicente E, Rojas-Garcia R, Díaz-Manera J, et al. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. Ann Clin Transl Neurol. 2018;5(6):710–716.
- Peres J, Martins R, Alves JD, et al. Rituximab in generalized myasthenia gravis: clinical, quality of life and cost–utility analysis. Porto Biomedical Journal. 2017;2(3):81–85.
- Stieglbauer K, Pichler R, Topakian R. 10-year-outcomes after rituximab for myasthenia gravis: efficacy, safety, costs of inhospital care, and impact on childbearing potential. J Neurol Sci. 2017;375:241–244.
- Sudulagunta SR, Sepehrar M, Sodalagunta MB, et al. Refractory myasthenia gravis - clinical profile, comorbidities and response to rituximab. German Medical Science : GMS E-journal. 2016;14(Doc12). DOI:10.3205/000239.
- Topakian R, Zimprich F, Iglseder S, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019;266(3):699–706.
- Anderson D, Phan C, Johnston WS, et al. Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up. Ann Clin Transl Neurol. 2016;3(7):552–555.
- Jing S, Song Y, Song J, et al. Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis. J Neuroimmunol. 2017;311:14–21.
- Landon-Cardinal O, Friedman D, Guiguet M, et al. Efficacy of rituximab in refractory generalized anti-AchR myasthenia gravis. J Neuromuscul Dis. 2018;5(2):241–249.
- Dos Santos A, Noury JB, Genestet S, et al. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur J Neurol. 2020;27(11):2277–2285.
- Iorio R, Damato V, Alboini PE, et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2015;262(5):1115–1119.
- A study evaluating the safety and efficacy of rituximab in patients with myasthenia gravis. Accessed 2020 Jun 24. https://clinicaltrials.gov/ct2/show/NCT02950155
- Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. Neurol Clin Pract. 2016;6(2):e17–e19.
- Rituximab FDA information. [cited 2020 Jun 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf
- Greenwald M, Tesser J, Sewell KL. Biosimilars have arrived: rituximab. Arthritis. 2018;2018:3762864.
- Banerjee S, Adcock L. Rituximab for the Treatment of Myasthenia Gravis: a Review of Clinical Effectiveness. and Guidelines. Canadian Agency for Drugs and Technologies in Health: Cost-Effectiveness; 2019.
- Meriggioli MN. Myasthenia Gravis: Immunopathogenesis, diagnosis and managemnet. Continuum. 2009;15:35–62.